title: Role of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor in the Development of Chronic Subdural Hematoma.
abstract: Chronic subdural hematoma (CSDH) is an inflammatory and angiogenic disease. Vascular endothelial growth factor (VEGF) has an important effect on the pathological progression of CSDH. The matrix metalloproteinases (MMPs) and VEGF also play a significant role in pathological angiogenesis. Our research was to investigate the level of MMPs and VEGF in serum and hematoma fluid. Magnetic Resonance Imaging (MRI) shows the characteristics of different stages of CSDH. We also analyzed the relationship between the level of VEGF in subdural hematoma fluid and the appearances of the patients' MRI. We performed a study comparing serum and hematoma fluid in 37 consecutive patients with primary CSDHs using enzyme-linked immunosorbent assay (ELISA). MMP-2 and MMP-9 activity was assayed by the gelatin zymography method. The patients were divided into five groups according to the appearance of the hematomas on MRI: group 1 (T1-weighted low, T2-weighted low, n=4), group 2 (T1-weighted high, T2-weighted low, n=11), group 3 (T1-weighted mixed, T2-weighted mixed, n=9), group 4 (T1-weighted high, T2-weighted high, n=5), and group 5 (T1-weighted low, T2-weighted high, n=8). Neurological status was assessed by Markwalder score on admission and at follow-up. The mean age, sex, and Markwalder score were not significantly different among groups. The mean concentration of VEGF, MMP-2, and MMP-9 were significantly higher in hematoma fluid than in serum (p<0.01). The level of pro-MMP-2 was higher in hematoma fluid (p<0.01). Measurement of MMP-9 showed both pro and active forms in both groups, but levels were higher in hematoma fluid (p<0.01 and p<0.01, respectively). Mean VEGF concentration was highest in group 1 (21,979.3±1387.3 pg/mL), followed by group 2 (20,060.1±1677.2 pg/mL), group 3 (13,746.5±3529.7 pg/mL), group 4 (7523.2±764.9 pg/mL), and lowest in group 5 (6801.9±618.7 pg/mL). There was a significant correlation between VEGF concentrations and MRI type (r=0.854). The present investigation is the first report showing that the concentrations of MMP-2 and MMP-9 are significantly elevated in hematoma fluid, suggesting that the MMPs/VEGF system may be involved in the angiogenesis of CSDH. We also demonstrate a significant correlation between the concentrations of VEGF and MRI appearance. This finding supports the hypothesis that high VEGF concentration in the hematoma fluid is of major pathophysiological importance in the generation and steady increase of the hematoma volume, as well as the determination of MRI appearance.
authors: 1 Department of Neurosurgery, Norman Bethune College of Medicine, Jilin University , Changchun, China .
authors: Cong
authors: C
authors: Hua
authors: 1 Department of Neurosurgery, Norman Bethune College of Medicine, Jilin University , Changchun, China .
authors: Gang
authors: G
authors: Zhao
authors: 2 Department of Radiology of the First Hospital, Norman Bethune College of Medicine, Jilin University , Changchun, China .
authors: Yan
authors: Y
authors: Feng
authors: 3 Department of Immunology, Norman Bethune College of Medicine, Jilin University , Changchun, China .
authors: Hongyan
authors: H
authors: Yuan
authors: 1 Department of Neurosurgery, Norman Bethune College of Medicine, Jilin University , Changchun, China .
authors: Hongmei
authors: H
authors: Song
authors: 1 Department of Neurosurgery, Norman Bethune College of Medicine, Jilin University , Changchun, China .|4 Department of Pathology and Laboratory Medicine, University of California , Irvine, California.
authors: Li
authors: L
authors: Bie
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003399:Craniotomy; D005260:Female; D020200:Hematoma, Subdural, Chronic / Q000097:blood / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000097:blood / Q000378:metabolism*; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000378:metabolism*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9
keywords: CSDH; MMP-2; MMP-9; MRI; VEGF
references: J Neurosurg. 2007 Aug;107(2):290-5
references: 17695382
references: Cell. 2000 Oct 27;103(3):481-90
references: 11081634
references: J Trauma. 1999 Mar;46(3):532-3
references: 10088869
references: Cancer Res. 1998 Mar 1;58(5):1048-51
references: 9500469
references: J Neurosurg. 1997 Dec;87(6):870-5
references: 9384397
references: J Neurosurg. 1987 Nov;67(5):677-83
references: 3668635
references: Cancer Cell. 2004 Oct;6(4):347-60
references: 15488758
references: J Neurosurg. 2003 Nov;99(5):824-30
references: 14609160
references: Angiogenesis. 2002;5(3):215-26
references: 12831062
references: Nat Rev Cancer. 2003 Jun;3(6):401-10
references: 12778130
references: J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42
references: 12165638
references: Clin Cancer Res. 2002 Jan;8(1):144-8
references: 11801551
references: Acta Neurochir (Wien). 2001 Aug;143(8):811-8; discussion 819
references: 11678402
references: Surg Neurol. 2009 Feb;71(2):161-5; discussion 165-6
references: 18423527
references: Biochim Biophys Acta. 2009 Aug;1796(1):33-40
references: 19460418
references: J Biol Chem. 2009 Sep 18;284(38):25854-66
references: 19608737
references: Neurol Med Chir (Tokyo). 2009 Sep;49(9):379-85
references: 19779281
references: J Med Dent Sci. 2009 Sep;56(3):101-6
references: 20099472
references: Nature. 2011 May 19;473(7347):298-307
references: 21593862
references: J Neurotrauma. 2011 Jun;28(6):1127-31
references: 21309701
references: Brain Inj. 2012;26(3):291-7
references: 22372416
references: Brain Res. 2012 Dec 13;1489:98-103
references: 23063714
references: J Neurotrauma. 2013 Oct 15;30(20):1717-26
references: 23725031
references: J Neurol Sci. 2014 Jan 15;336(1-2):237-42
references: 24269089
references: J Neurotrauma. 2014 Apr 1;31(7):670-3
references: 24245657
references: Turk Neurosurg. 2014;24(3):363-8
references: 24848175
references: J Neurotrauma. 2014 Aug 15;31(16):1451-6
references: 24684589
references: J Clin Neurosci. 2001 Sep;8(5):411-5
references: 11535006
references: Semin Cell Dev Biol. 2008 Feb;19(1):34-41
references: 17707664
references: Nat Cell Biol. 2000 Oct;2(10):737-44
references: 11025665
references: Surg Neurol. 2000 Apr;53(4):312-5; discussion 315-7
references: 10825513
references: Circ Res. 2007 Mar 30;100(6):904-13
references: 17322177
references: Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):716-28
references: 16469948
references: Can J Neurol Sci. 2005 Nov;32(4):501-6
references: 16408582
references: Surg Neurol. 2005 Nov;64(5):444-9; discussion 449
references: 16253697
references: J Neurotrauma. 2005 May;22(5):518-28
references: 15892598
references: Cancer Res. 2005 Apr 15;65(8):3200-8
references: 15833851
references: Neuroradiology. 1999 Feb;41(2):109-16
references: 10090603